Ionizing radiation has many practical applications, but it is also, as it is well known, dangerous to human health. The purpose of this study was to estimate the dose and exposure for medical staff involved in sentinel node assay and to determine how safe this assay really is. The theoretical method was used for calculation. Three groups of medical staff were selected: nuclear medicine specialist, nuclear medicine technologist and a surgeon. The results obtained show that the most exposed staff member is nuclear medicine specialist and that dose received by the surgeon is smaller then the dose limit.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807967 | PMC |
http://dx.doi.org/10.17305/bjbms.2006.3118 | DOI Listing |
Alzheimers Dement
December 2024
Indiana University School of Medicine, Indianapolis, IN, USA.
Background: The goal of the TREAT-AD Center is to enable drug discovery by developing assays and providing tool compounds for novel and emerging targets. The role of microglia in neuroinflammation has been implicated in the pathogenesis of Alzheimer's disease (AD). Genome-wide association studies, whole genome sequencing, and gene-expression network analyses comparing normal to AD brain have identified risk and protective variants in genes essential to microglial function.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Keck School of Medicine at University of Southern California, Los Angeles, CA, USA.
Background: ABCA1-mediated cholesterol transport is a central feature in many lipid- dependent diseases including APOE4-associated Alzheimer's disease and atherosclerosis-CVD. ABCA1 upregulation of RNA transcription by nuclear factors (LXR, RXR) have been associated with liver side-effects because of the common promotor element for ABCA1 and Fatty Acid Synthase. The ABCA1 agonist CS6253, derived from the C-terminal of apoE was designed to stabilize and enhance ABCA1 function, thereby providing a safe alternative to transcriptional upregulation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Background: Amyloid imaging biomarkers serve an increasingly important role in diagnosing Alzheimer's disease and determining eligibility for treatment with new disease-modifying therapies. Yet, psychological and behavioral reactions to receiving a biomarker informed diagnosis remain relatively unstudied, especially in diverse and underserved populations where the burden of disease is high and resources for support are often insufficient. We developed the Patient And family member Reactions to biomarker-informed ADRD DiagnosEs (PARADE) Study to address two key gaps in our understanding: 1) the range and trajectory of psychological and behavioral responses to a biomarker informed diagnosis and 2) the support needs of these individuals and their families.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Brain Institute of Rio Grande do Sul - Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Background: Although cognitive decline is a trait related to aging, some individuals are resilient to the aging process, defined as SuperAgers. Studying the neural underpinnings of SuperAgers may improve the understanding of AD pathology. In this study, our aim was to analyze amyloid and neurodegeneration imaging biomarkers in SuperAgers.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Alzheimer's Disease Neuroimaging Initiative, http://adni.loni.usc.edu/, CA, USA.
Background: Amyloid and tau pathologies are the hallmarks of Alzheimer's disease (AD). Previous research indicated notable connections between financial capacity and AD biomarkers. Here, we aimed to understand whether financial capacity is affected by the cerebral accumulation of tau and amyloid.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!